Endometrial Cancer Trial, Recruiting NCT05709769 Sponsor: Zhejiang Provincial People's Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05709769
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had a radical hysterectomy (removal of the uterus and surrounding tissue) and pelvic lymph node removal, with a confirmed diagnosis of cervical cancer
  • People whose cervical cancer was classified as stage IB1 to IIA2 using the 2014 FIGO cervical cancer staging system
  • People who received post-surgery radiation therapy or chemotherapy combined with radiation, starting within one week of admission to the trial's treating hospital (ZJPPH)
  • People with a general health and activity level rated 0 to 2 on a standard medical performance scale, meaning they are able to carry out daily activities with little to no limitation
  • People who had no cancer treatments before their radical surgery
  • People whose recent blood test results (taken within 7 days of enrolling) show that bone marrow, liver, kidney, and heart function all fall within acceptable ranges set by the trial (confirm specific numbers with trial site)
  • People who are not known to be allergic to platinum-based chemotherapy drugs such as cisplatin or carboplatin, or to similar compounds
  • People who are willing to follow the trial's requirements, including accepting nutritional therapy as part of the study
  • People who have signed an informed consent form agreeing to participate

Who may not be able to join:

  • People whose medical scans have poor image quality or visible interference around a specific spinal muscle region used in the study's measurements (the L3 psoas area)
  • People who have previously received chemotherapy or radiation therapy
  • People whose bone marrow, liver, or kidney function is too poor to safely tolerate chemotherapy or radiation therapy
  • People who are currently taking part in another clinical trial
  • People who are pregnant, breastfeeding, or not using contraception
  • People with serious or uncontrolled medical conditions, which may include active uncontrolled infection, heart failure, unstable chest pain, irregular heartbeat, or significant mental health or social circumstances that would make it difficult to follow the study requirements
  • People who have had another active cancer diagnosis within the past five years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yongshi Jia, M.D., Zhejiang Provincial People's Hospital

Phone: +86-571-85893638

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Zhejiang Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
31 January 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Construction and Validation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov